HD10/HD21 (BEACON)

HD10/HD21 (BEACON)

HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD

Disease:

Hodgkin Lymphoma

Summary:

Hodgkin Lymphoma is an aggressive form of lymphoma, a cancer of blood cells, which particularly effects younger adults. Symptoms include enlarged lymph nodes, high temperature, sweating at night, weight loss, fatigue and itch.

This trial is for patients with advanced stage of Hodgkin Lymphoma who have not been treated for their lymphoma before. Patients will be randomised (50:50) between receiving the current standard combination of chemotherapy drugs (intravenously and orally), and the addition of a lymphoma targeting antibody called brentuximab (intravenous) to chemotherapy.

The aim of the trial is to see whether brentuximab added to chemotherapy is as effective in treating lymphoma as currently used chemotherapy.

Eligibility:

Include, but not limited to, the following:

Inclusion Criteria:
1. Histologically proven classical Hodgkin lymphoma
2. First diagnosis, no previous treatment, 18 to 60 years of age
3. Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV

Exclusion Criteria:
1. Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma
2. Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
3. Prior chemotherapy or radiotherapy

Contact person:

Louise Hay
Email louise.hay@health.wa.gov.au
Phone 6457 7600


Email
Phone

Principal Investigator:

Dr Julie Crawford

6457 7600

Sponsor:

Australasian Leukaemia and Lymphoma Group

Phase:

III

Protocol Number:

ALLG H10/GHSG HD21

Trial Registration Number:

NCT02661503

Clinical Trials.gov

ANZ Clinical Trial Registry